You are here

Funding

Inter-CFAR Fellowship Program in Implementation Science - Expiration Date: November 7, 2020

On behalf of inter-CFAR Implementation Science Working Group, we are welcoming applications for an NIH-funded training opportunity in implementation science (IS) for early stage investigators (ESIs) engaging in HIV-related research. In 2019-2020, 27 inaugural fellows participated. The Fellowship has been renewed and will be open to 24 Fellows in the upcoming cohort. Implementation Science Fellows will be selected across the CFAR network to participate in a mentorship program, including both didactic online and mentored small group training in IS methodology. The applied mentorship focuses on the development of a grant application which incorporates implementation science methodology and/or training and is intended to culminate in a two-day grant refinement and networking workshop.

Fellows will be expected to complete a series of 10 pre-recorded modules, attend 8 of 10 live sessions to discuss the lectures and critical papers in the field, advance the development of a grant incorporating implementation science research, and attend a two-day in-person workshop with the mentorship team. Although we are hoping to meet in person in April 2021, a final decision regarding the in-person meeting will be determined at a later date due to the Covid-19 pandemic.

The overarching goal of the fellowship is to support ESIs focused on HIV-related research with training and mentoring opportunities in IS to encourage and capacitate ESIs in the submission of successful IS-focused grants. Specifically, the objectives are:

  1. Fill an implementation science training gap among emergent HIV-focused investigators
  2. Support ESIs in the development of an implementation science focused grant
  3. Foster cross-institutional networking and mentorship opportunities for ESIs within the field of HIV-implementation science

Mentoring Team: Stefan Baral (JHU), Bhakti Hansoti (JHU), Chris Hoffmann (JHU), Elvin Geng (Washington University in St. Louis), Vivian Go (UNC), Arianna Means (Washington University), Sharmistha Mishra (St. Michael’s Hospital), Denis Nash (CUNY), Sheree Schwartz (JHU), Kenneth Sherr (Washington University), J.D. Smith (Utah SOM), Patrick Sullivan (Emory)

Eligibility and logistics: Spots will be reserved exclusively for junior faculty (Assistant Professor, Research Assistant Professor and equivalent positions), post-doctoral fellows and exceptional senior-level PhD candidates. Applicants will be asked to submit their NIH formatted biosketch, a one page specific aims document pertaining to the grant that they will be developing, provide basic details of their proposed IS-related grant (e.g. working title, funding mechanism, submission cycle), and a brief summary of their prior experience and planned future directions conducting implementation science research. The specific aims page does not need to be polished and is expected to evolve during the fellowship as IS skills advance. Because grant development is critical to the fellowship, however, we are seeking out applicants who will be submitting a grant that incorporates IS methodology and are committed to moving this forward. Funding will be available for the IS Fellows to attend the 2-day in-person meeting planned for April 2021.

Interested applicants should apply online by October 18, 2020 11:59 pm EST at:

http://jhsph.co1.qualtrics.com/jfe/form/SV_72pIEEogfP1VYup

Outcomes will be announced by November 7, 2020. The virtual fellowship will begin in November 2020.

Please direct questions to Sheree Schwartz, PhD: sschwartz@jhu.edu and Lisa Lucas llucas11@jhmi.edu

Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional) - Expiration Date: November 13, 2020
  • Participating Organization(s) and Components: National Institutes of Health (NIH), Fogarty International Center (FIC), National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Cancer Institute (NCI)
  • Purpose: The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or caregivers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).
  • Open Date: October 12, 2019
  • Amount of Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $150,000 may be requested in any single year. The budget request must reflect the actual needs of the proposed project.
  • Due Date: November 12, 2019, November 12, 2020  by 5:00 PM local time of applicant organization
  • More Information: https://grants.nih.gov/grants/guide/pa-files/PAR-19-326.html
  • End Date: November 13, 2020
High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional) - Expiration Date: January 8, 2021
Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) - Expiration Date: April 30, 2021
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
  • Open Date: April 30, 2020
  • Amount of Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
  • Due Date:

    Applications will be accepted on a rolling basis, beginning on 04/30/2020.

    All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • More Information: NIH
  • Expiration Date: April 30, 2021
Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) - Expiration Date: April 30, 2021
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
  • Open Date: April 30, 2020
  • Amount of Award: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year..
  • Due Date:

    Applications will be accepted on a rolling basis, beginning on 04/30/2020.

    All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

  • More Information: NIH
  • Expiration Date: April 30, 2021
NIAID New Innovator PAR for post-doctoral fellows - Expiration Date: October 14, 2021

As part of the NIAID commitment to increase opportunities for post-doctoral fellows, the NIAID New Innovator Award (DP2), PAR-19-296, was published last week. The purpose is to support post-doctoral investigators of exceptional creativity who propose highly innovative bold new research with the potential to produce a major impact on broad, important problems in biomedical research relevant to the mission of NIAID. Applicants approved for funding would have one year to secure an independent, tenure-track (or equivalent) faculty position at an U.S. extramural institution to activate the award.  Through this initiative, NIAID wants to encourage shorter post-doctoral fellowships and provide the opportunity for creative scientists with little to no preliminary data to start their independent careers earlier. NIAID intends to award up to 10 applications per year.
 
Please share this FOA with any talented non-independent postdocs (research and/or clinical doctorate degree, U.S. or non-U.S. citizens), as well as with investigators who may know of appropriate candidates. The next receipt date is November 4, 2019 (once per year); clinical trials are not allowed for this FOA. The DAIDS contact for this PAR is Diane Lawrence.  Her contact info is below:
 
Diane Lawrence, Ph.D.
Program Officer, Pathogenesis and Basic Research Branch
Basic Science Program, Division of AIDS, NIAID
5601 Fishers Lane, Rm 9G22
Bethesda, MD 20892
240-627-3202, lawrencedi@niaid.nih.gov

Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional) Expiration Date: November 18, 2021
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Purpose:The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental mechanisms underlying HIV-associated comorbidities, coinfections, and complications relevant to the mission of the NIDDK and advance progress toward alleviating them.
  • Open Date: February 3, 2021
  • Amount of Award: Application budgets are limited to $500,000 direct costs per year and should reflect the actual needs of the proposed project.
  • Due Date: March 3, 2021 and November 17, 2021
    All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • More Information: NIH
  • Expiration Date: November 18, 2021
Toward ElucidAting MechanismS Contributing to HIV Reservoirs in NIDDK-relevant Tissues (Cure TEAMS) (R01 Clinical Trial Optional) Expiration Date: November 18, 2021
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and physiology, pathophysiology, pathobiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will provide comprehensive mechanistic analyses of the processes leading to the establishment and persistence of latent HIV reservoirs in anatomical sites relevant to the mission of the NIDDK, with the purpose of advancing progress toward developing a cure.
  • Open Date: February 3, 2021
  • Amount of Award: Application budgets are limited to $500,000 direct costs per year and should reflect the actual needs of the proposed project.
  • Due Date: March 3, 2021 and November 17, 2021
    All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • More Information: NIH
  • Expiration Date: November 18, 2021
Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional) - Expiration Date: December 15, 2021
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Cancer Institute (NCI)
  • Purpose: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to advance our understanding of: the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and the risk factors for infection. Such studies should inform and advance efforts to reduce or eliminate KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of HIV infection.
  • Open Date: November 13, 2020
  • Amount of Award: Application budgets should reflect the actual needs of the proposed project. Application budgets may not exceed $500,000 direct costs per year
  • Due Date: December 15, 2020; December 14, 2021

    No late applications will be accepted for this Funding Opportunity Announcement.

    All applications are due by 5:00 PM local time of applicant organization.

  • More Information: NIH
  • Expiration Date: December 15, 2021
Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional) - Expiration Date: September 8, 2022
  • Participating Organization(s) and Components: National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)
  • Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support grants to improve understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology, novel tools from data science approaches and m/eHealth, and implementation science research. Data generated through this research will be used to inform and evaluate context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.
  • Open Date: December 7, 2019
  • Amount of Award: Application budgets are not limited but need to reflect the actual needs of the proposed project.
  • Due Date:Standard AIDS dates apply.
    All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).
    Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • More Information: NIH
  • Expiration Date: September 8, 2022
CFAR Adelante 2021Funding Opportunity - Expiration Date: July 31, 2023

The NIH has opened the 2021 Adelante RFA.

Adelante - meaning forward or onward in Spanish – is funded by the NIH/NIMHD and administered through two NIH-funded Center for AIDS Research (CFARs): District of Columbia and Emory University. Through this program, the NIH strives to promote the mentored development of early-career investigators who focus on HIV/AIDS prevention, treatment, and care in Latinx communities.

The Adelante program supports 2-year Adelante Teams consisting of a scholar (Early Stage Investigator), a CFAR affiliated mentor, and a collaborating partner who is a representative from a Community-based Organization that serves Latinx populations. Adelante teams should be supportive and interdisciplinary. Proposed research should be community-based and reflect local Hispanic/Latinx-community needs, as identified by science and the local community. Research proposal topics may include but are not limited to: 

  • Developing, testing, and implementing strategies to improve HIV testing and entry into prevention services by Latinx/Hispanic people.
  • Long-term prevention strategies specific to Latinx populations for HIV-relevant coinfections and comorbid conditions across the lifespan
  • Effective socio-behavioral interventions to achieve uptake of HIV prevention and treatment strategies by Latino/Hispanic people and reduce health disparities among Latinx populations.
  • Implementation research tailored specifically for Latinx populations that is designed to ensure that biomedical and other prevention and treatment strategies are initiated as soon as possible, that retention and engagement in treatment services is increased, and/or that maintenance of optimal prevention and treatment responses are achieved.
  • Research that examines HIV-related health and social issues in Latinx populations, such as other infectious or non-infectious conditions and substance use or mental health disorders that are clearly linked with HIV (transmission/acquisition, pathogenesis, morbidity and mortality, stigma) in sub-populations or settings with high HIV prevalence or incidence.

Applicants may request up to $100,000 in direct costs per year ($200,000 over two years) plus applicable indirect costs, not to exceed direct costs per year. This funding may be used for salaries, technical support, laboratory supplies, equipment, and for research- or training-related activities including but not limited to enrollment in training classes or workshops, travel to the CFAR Mentor's institution, or travel to the research field site.

You can find the Adelante Fact Sheet here and more information about the program including the full RFA at the Adelante website here.